Quinidine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
- Quinidine
- Quinidine: From Unknown Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis
Quinidine: From Unknown Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Quinidine’s original approved indication and mechanism of action are not available in the current evidence pack. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model prediction with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indication on file; drug is not marketed in the US) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.27% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for quinidine is not currently available in this evidence pack, and no original approved indication is on file. As a result, no mechanistic or clinical linkage between quinidine and the predicted indication (nephrogenic syndrome of inappropriate antidiuresis) can be established from the data at hand.
Without MOA data, original indication data, clinical trial evidence, or published literature, this prediction rests solely on the TxGNN knowledge-graph score. While the score itself is high (99.27%), a high model score alone does not constitute pharmacological or clinical justification — it should be treated as a hypothesis-generation signal only, pending mechanistic review and evidence collection.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
Quinidine is not currently marketed in the US (market status: 未上市, 0 licenses on file). No authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate lacks core inputs required for even a preliminary safety and mechanistic assessment — MOA is unknown, the original indication is undocumented, and there is no clinical trial or literature evidence supporting the predicted indication. The TFDA warning/contraindication data gap is flagged as Blocking, which by itself prevents entry into S1 safety screening.
To proceed, the following is needed:
- TFDA (or equivalent regulatory) package insert warnings and contraindications (Blocking gap, DG001)
- Confirmed mechanism of action from DrugBank or primary literature (DG002)
- Documentation of quinidine’s original approved indication(s)
- At least preliminary literature or preclinical evidence linking quinidine to nephrogenic syndrome of inappropriate antidiuresis before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.